ARCT vs. VERA, ETNB, BHVN, ANIP, MESO, EWTX, JANX, TVTX, GPCR, and CVAC
Should you be buying Arcturus Therapeutics stock or one of its competitors? The main competitors of Arcturus Therapeutics include Vera Therapeutics (VERA), 89BIO (ETNB), Biohaven (BHVN), ANI Pharmaceuticals (ANIP), Mesoblast (MESO), Edgewise Therapeutics (EWTX), Janux Therapeutics (JANX), Travere Therapeutics (TVTX), Structure Therapeutics (GPCR), and CureVac (CVAC). These companies are all part of the "pharmaceutical products" industry.
Arcturus Therapeutics vs. Its Competitors
Arcturus Therapeutics (NASDAQ:ARCT) and Vera Therapeutics (NASDAQ:VERA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.
94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 15.3% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 16.3% of Vera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Arcturus Therapeutics had 5 more articles in the media than Vera Therapeutics. MarketBeat recorded 7 mentions for Arcturus Therapeutics and 2 mentions for Vera Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.80 beat Vera Therapeutics' score of 0.56 indicating that Arcturus Therapeutics is being referred to more favorably in the media.
Arcturus Therapeutics has a beta of 2.27, suggesting that its share price is 127% more volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.
Vera Therapeutics has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -47.47%. Arcturus Therapeutics' return on equity of -27.41% beat Vera Therapeutics' return on equity.
Arcturus Therapeutics currently has a consensus target price of $54.00, indicating a potential upside of 304.19%. Vera Therapeutics has a consensus target price of $65.00, indicating a potential upside of 182.98%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Arcturus Therapeutics is more favorable than Vera Therapeutics.
Arcturus Therapeutics has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Arcturus Therapeutics beats Vera Therapeutics on 12 of the 16 factors compared between the two stocks.
Get Arcturus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ARCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcturus Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ARCT) was last updated on 7/7/2025 by MarketBeat.com Staff
